Aplastic anaemia (AA) is a rare but serious acquired bone marrow failure disorder of considerable clinical similarity to the hypoplastic type of MDS.  In same cases AA  may also progress […]

Daisy Turner and her MDS experience   We are pleased to share the story of a very brave and inspirational young MDS patient – Daisy Turner. Daisy was diagnosed with […]

  World Cancer Day is a truly global event to unite the world’s population in the fight against cancer. Its aim is to raise awareness that there is much that […]

Cancer Drug Fund – 20/01/15 The CDF team was recently forced to remove 20 drugs from the list of drugs they fund – in order to balance the budget allocated […]

Leukaemia and Lymphoma Grant for research into Familial MDS MDS is not considered a hereditary disease – but there is a very small percentage of cases where 2 or 3 […]

TED talk on MDS/AML research by expert Dr Azra Raza. Published on 15 Jan 2015 Cancer research relies heavily on testing drugs in mice — yet it’s clear that for […]

NICE – National Institute for Health and Clinical Excellence – finally recommend azacitidine is available through the NHS for intermediate 2 and high-risk MDS, AML and CMML for England and Wales. The MDS UK Patient Support Group, which has been in consultation with NICE during the approval process and campaigned on behalf and in conjunction with MDS patients across the UK for almost 2 years, welcomes this announcement.

Full details in the news page.

ULTRA Challenge series in 2015 Walk it, Jog it or Run it – choose your distance!  It’s Your Challenge – Your Way! If you’re looking for a challenge in 2015 […]